12 Hospital Physician Board Review Manual www.turner-white.com
cetuximab, capecitabine and radiotherapy in neoadjuvant
treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol 2010;36:244–50.
53. Helbling D, Bodoky G, Gautschi O, et al. Neoadjuvant
chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer
(LARC): a randomized, multicenter, phase II trial SAKK
41/07. Ann Oncol 2012;24:718–25.
54. Gérard J-P, Azria D, Gourgou-Bourgade S, et al. Clinical
outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012;30:4558–65.
55. Aschele C, Cionini L, Lonardi S, et al. Primary tumor
response to preoperative chemoradiation with or without
oxaliplatin in locally advanced rectal cancer: pathologic
results of the STAR-01 randomized phase III trial. J Clin
56. Schmoll H-J, Haustermans K, Price TJ, et al. Preoperative
chemoradiotherapy and postoperative chemotherapy with
capecitabine and oxaliplatin versus capecitabine alone
in locally advanced rectal cancer: disease-free survival
results at interim analysis. ASCO Annual Meeting 2014;
Chicago; May 30–June 3, 2014. Abstract 3501.
57. Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally
advanced rectal cancer: initial results of the German CAO/
ARO/AIO-04 randomised phase 3 trial. Lancet Oncol
58. Rodel C, Liersch T, Fietkau R, et al: Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluo-
rouracil and oxaliplatin versus 5-fluorouracil alone in locally
advanced rectal cancer: Results of the German CAO/ARO/
AIO-04 randomized phase III trial. ASCO Annual Meeting
2014; Chicago; May 30–June 3, 2014. Abstract 3500.
59. Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant
chemotherapy without routine use of radiation therapy for
patients with locally advanced rectal cancer: a pilot trial. J
Clin Oncol 2014;32:513–8.
60. Palta M, Willett C, Czito B. Neoadjuvant chemotherapy
alone in locally advanced rectal cancer: an interesting
PROSPECT but not ready for primetime. 2014 Gastrointestinal Cancer Symposium Daily News. January 17, 2014.
61. Bujko K, Nowacki M, Nasierowska-Guttmejer A, et al.
Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer.
Br J Surg 2006;93:1215–23.
62. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative
radiotherapy combined with total mesorectal excision for
resectable rectal cancer. N Engl J Med 2001;345:638–46.
63. Stein DE, Mahmoud NN, Anné PR, et al. Longer time in-
terval between completion of neoadjuvant chemoradiation
and surgical resection does not improve downstaging of
rectal carcinoma. Dis Colon Rectum 2003;46:448–53.
64. Fokas E, Liersch T, Fietkau R, et al. Tumor regression
grading after preoperative chemoradiotherapy for locally
advanced rectal carcinoma revisited: Updated results of
the CAO/ARO/AIO-94 trial. J Clin Oncol 2014;32:1554–62.
65. Sainato A, Nunzia VCL, Valentini V, et al. No benefit of
adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of
the rectum (LARC): Long term results of a randomized trial
(I-CNR-RT). Radiother Oncol 2014;113:223–9.
66. Breugom A, van Gijn W, Muller E, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo) radiotherapy and total mesorectal excision:
a Dutch Colorectal Cancer Group (DCCG) randomised
phase III trial. Ann Oncol 2015;26:696–701.
67. Breugom AJ, Swets M, Bosset J-F, et al. Adjuvant chemotherapy after preoperative (chemo) radiotherapy and
surgery for patients with rectal cancer: a systematic review
and meta-analysis of individual patient data. Lancet Oncol
68. Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for
patients with resected rectal cancer who have already
received neoadjuvant radiochemotherapy? A systematic
review of randomised trials. Ann Oncol 2010;21:1743–50.
69. Wales Cancer Trials Unit. Oxaliplatin, Leucovorin, and
Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be
Removed by Surgery (COPERNICUS). ClinicalTrials.gov
Accessed August 6, 2015.
70. Oncology AfCTi. PROSPECT: Chemotherapy Alone or
Chemotherapy Plus Radiation Therapy in Treating Patients
With Locally Advanced Rectal Cancer Undergoing Surgery. ClinicalTrials.gov website. https://clinicaltrials.gov/
ct2/show/NCT01515787. Accessed August 6, 2015.
71. Hong YS, Nam BH, Kim KP, et al. Oxaliplatin, fluorouracil,
and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after
preoperative chemoradiotherapy (ADORE): an open-label,
multicentre, phase 2, randomised controlled trial. Lancet
72. Benson AB, Venook AP, Bekaii-Saab T, et al. Rectal Cancer,
Version 2.2015. J Natl Compr Canc Netw 2015;13:719–28.
73. Meyerhardt JA, Mangu PB, Flynn PJ, et al. Follow-up care,
surveillance protocol, and secondary prevention measures
for survivors of colorectal cancer: American Society of
Clinical Oncology clinical practice guideline endorsement.
J Clin Oncol 2013;31:4465–70.